Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Treating CLL with obinutuzumab

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 17.06.18
Views: 487

Dr Valentin Goede - St. Marien-Hospital, Cologne, Germany

Dr Goede speaks with ecancer at EHA 23 about the use of CD20 targeted antibody obinutuzumab compared to rituximab in combination with chlorambucil chemotherapy.

He describes the 3 arms of the trial, which found the combination of obinutuzumab and chemotherapy progression free survival and overall survival compared to rituximab, and considers future CD20 based combinations and therapies.

For more on these findings, watch his presentation of the results at a press session here.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

NCRI 2018


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence